These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31517638)

  • 41. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
    Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
    BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm.
    Cho Y; Lim SK; Joo SK; Jeong DH; Kim JH; Bae JM; Park JH; Chang MS; Lee DH; Jung YJ; Kim BG; Kim D; Lee KL; Kim W
    Liver Int; 2019 Sep; 39(9):1722-1731. PubMed ID: 31162812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
    Younossi ZM; Noureddin M; Bernstein D; Kwo P; Russo M; Shiffman ML; Younes Z; Abdelmalek M
    Am J Gastroenterol; 2021 Feb; 116(2):254-262. PubMed ID: 33284184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ethnicity and nonalcoholic fatty liver disease.
    Bambha K; Belt P; Abraham M; Wilson LA; Pabst M; Ferrell L; Unalp-Arida A; Bass N;
    Hepatology; 2012 Mar; 55(3):769-80. PubMed ID: 21987488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Zhang F; Han Y; Wu Y; Bao Z; Zheng G; Liu J; Li W
    Ann Med; 2024 Dec; 56(1):2409342. PubMed ID: 39348274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
    Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
    Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
    Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.
    Neuschwander-Tetri BA; Clark JM; Bass NM; Van Natta ML; Unalp-Arida A; Tonascia J; Zein CO; Brunt EM; Kleiner DE; McCullough AJ; Sanyal AJ; Diehl AM; Lavine JE; Chalasani N; Kowdley KV;
    Hepatology; 2010 Sep; 52(3):913-24. PubMed ID: 20648476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians.
    Satapathy SK; Marella HK; Heda RP; Ganguli S; Kirthi Reddy Y; Podila PSB; Clark I; Maliakkal B
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):388-398. PubMed ID: 32317586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 60. Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men.
    Kim JK; Chon NR; Lim HC; Lee KS; Han KH; Chon CY; Park YN; Paik YH
    J Gastroenterol Hepatol; 2012 Jan; 27(1):142-8. PubMed ID: 21883454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.